Works matching IS 01676997 AND DT 2017 AND VI 35 AND IP 5

Results: 17

ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 599, doi. 10.1007/s10637-017-0433-4

By:

Crabb, Simon;
Birtle, Alison;
Martin, Karen;
Downs, Nichola;
Ratcliffe, Ian;
Maishman, Tom;
Ellis, Mary;
Griffiths, Gareth;
Thompson, Stuart;
Ksiazek, Lidia;
Khoo, Vincent;
Jones, Robert

Publication type:

Article

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 608, doi. 10.1007/s10637-017-0441-4

By:

Arnold, Susanne;
Chansky, Kari;
Leggas, Markos;
Thompson, Michael;
Villano, John;
Hamm, John;
Sanborn, Rachel;
Weiss, Glen;
Chatta, Gurkamal;
Baggstrom, Maria

Publication type:

Article

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 616, doi. 10.1007/s10637-017-0442-3

By:

Mita, Monica;
Fu, Siqing;
Piha-Paul, Sarina;
Janku, Filip;
Mita, Alain;
Natale, Ronald;
Guo, Wei;
Zhao, Charles;
Kurzrock, Razelle;
Naing, Aung

Publication type:

Article

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 627, doi. 10.1007/s10637-017-0444-1

By:

Diamond, Jennifer;
Goff, Barbara;
Forster, Martin;
Bendell, Johanna;
Britten, Carolyn;
Gordon, Michael;
Gabra, Hani;
Waterhouse, David;
Poole, Mark;
Ross Camidge, D.;
Hamilton, Erika;
Moore, Kathleen

Publication type:

Article

Resistance to immunotherapy: clouds in a bright sky.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 649, doi. 10.1007/s10637-017-0456-x

By:

Milano, Gérard

Publication type:

Article

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 576, doi. 10.1007/s10637-017-0459-7

By:

Infante, Jeffrey;
Cohen, Roger;
Kim, Kevin;
Burris, Howard;
Curt, Gregory;
Emeribe, Ugochi;
Clemett, Delyth;
Tomkinson, Helen;
LoRusso, Patricia

Publication type:

Article

New doxorubicin nanocarriers based on cyclodextrins.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 539, doi. 10.1007/s10637-017-0461-0

By:

Viale, Maurizio;
Giglio, Valentina;
Monticone, Massimiliano;
Maric, Irena;
Lentini, Giovanni;
Rocco, Mattia;
Vecchio, Graziella

Publication type:

Article

Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 662, doi. 10.1007/s10637-017-0462-z

By:

Matama, Goushi;
Tokito, Takaaki;
Takeoka, Hiroaki;
Hiraoka, Yuki;
Matsuo, Norikazu;
Nakamura, Masayuki;
Ishii, Hidenobu;
Kinoshita, Takashi;
Azuma, Koichi;
Yamada, Kazuhiko;
Hoshino, Tomoaki

Publication type:

Article

Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 545, doi. 10.1007/s10637-017-0465-9

By:

Olbryt, Magdalena;
Rusin, Aleksandra;
Fokt, Izabela;
Habryka, Anna;
Tudrej, Patrycja;
Student, Sebastian;
Sochanik, Aleksander;
Zieliński, Rafał;
Priebe, Waldemar

Publication type:

Article

Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 665, doi. 10.1007/s10637-017-0469-5

By:

Adrianzen Herrera, Diego;
Fleisig, Sarah;
Gartrell, Benjamin

Publication type:

Article

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 556, doi. 10.1007/s10637-017-0470-z

By:

Mori, Masamichi;
Kaneko, Naoki;
Ueno, Yoko;
Yamada, Masaki;
Tanaka, Ruriko;
Saito, Rika;
Shimada, Itsuro;
Mori, Kenichi;
Kuromitsu, Sadao

Publication type:

Article

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 634, doi. 10.1007/s10637-017-0473-9

By:

Almhanna, Khaldoun;
Wright, David;
Mercade, Teresa;
Van Laethem, Jean-Luc;
Gracian, Antonio;
Guillen-Ponce, Carmen;
Faris, Jason;
Lopez, Carolina;
Hubner, Richard;
Bendell, Johanna;
Bols, Alain;
Feliu, Jaime;
Starling, Naureen;
Enzinger, Peter;
Mahalingham, Devalingham;
Messersmith, Wells;
Yang, Huyuan;
Fasanmade, Adedigbo;
Danaee, Hadi;
Kalebic, Thea

Publication type:

Article

Gankyrin as a potential therapeutic target for cancer.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 655, doi. 10.1007/s10637-017-0474-8

By:

Wang, Chongchong;
Cheng, Li

Publication type:

Article

Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 566, doi. 10.1007/s10637-017-0477-5

By:

Zhen, Zijun;
Yang, Kaibin;
Ye, Litong;
You, Zhiyao;
Chen, Rirong;
Liu, Ying

Publication type:

Article

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Published in:

2017

By:

Infante, Jeffrey;
Cohen, Roger;
Kim, Kevin;
Burris, Howard;
Curt, Gregory;
Emeribe, Ugochi;
Clemett, Delyth;
Tomkinson, Helen;
LoRusso, Patricia

Publication type:

Erratum

Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 642, doi. 10.1007/s10637-017-0482-8

By:

Igawa, Satoshi;
Otani, Sakiko;
Ryuge, Shinichiro;
Fukui, Tomoya;
Nakahara, Yoshiro;
Hiyoshi, Yasuhiro;
Ishihara, Mikiko;
Kusuhara, Seiichiro;
Harada, Shinya;
Mitsufuji, Hisashi;
Kubota, Masaru;
Sasaki, Jiichiro;
Masuda, Noriyuki

Publication type:

Article

Pharmacokinetics and excretion of C-Plitidepsin in patients with advanced cancer.

Published in:

Investigational New Drugs, 2017, v. 35, n. 5, p. 589, doi. 10.1007/s10637-017-0432-5

By:

van Andel, L.;
Fudio, S.;
Rosing, H.;
Munt, S.;
Miguel-Lillo, B.;
González, I.;
Tibben, M.;
de Vries, N.;
de Vries Schultink, A.;
Schellens, J.;
Beijnen, J.

Publication type:

Article